Oxervate
Payments companies reported to CMS as associated with Oxervate. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Oxervate, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Oxervate
These are the largest totals companies reported as associated with Oxervate. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| John Affeldt | Loma Linda, CA | Ophthalmology | $141,709.72 |
| John Sheppard | Norfolk, VA | Ophthalmology | $96,888.73 |
| Cecelia Koetting | Aurora, CO | Optometrist | $91,849.90 |
| Nishi Shah | Phoenix, AZ | Ophthalmology | $72,948.65 |
| Jeffrey Goshe | Cleveland, OH | Ophthalmology | $72,459.57 |
| Douglas Devries | Sparks, NV | Optometrist | $71,211.82 |
| Paul Karpecki | Lexington, KY | Optometrist | $64,727.42 |
| Elise Kramer | Miami, FL | Optometrist | $62,621.89 |
| Gregory Caldwell | Duncansville, PA | Optometrist | $60,353.72 |
| Timothy Poirier | Knightdale, NC | Optometrist | $60,202.35 |
Prescribed Oxervate?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.